Proactive Investors
11 Nov 2025, 18:38 UTC · 45w ago
Verdict
Headline takes no side. We score ATAI +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
AtaiBeckley's BPL-003 Phase 2b results for treatment-resistant depression showed significant single-dose durability with a 63% response rate and 48% remission in open-label extension.
More positive than 99% of claims this week
Jefferies issued a 'Buy' rating on ATAI with a $10 price target, suggesting a 130% upside from current levels.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The company expects an FDA end-of-Phase 2 meeting in Q1 2026 and the initiation of two pivotal Phase 3 studies in Q2 2026.
More positive than 77% of claims this week
BPL-003 has received Breakthrough Therapy Designation from the FDA.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Positive Phase 2b results for BPL-003, a 'Buy' rating from Jefferies with a 130% upside, and strong year-to-date share price growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
5h ago
+69.0%
Price agrees with the score
$7.35 vs $4.35 close before publication (Nov 10) · not market-adjusted
ATAI chart →
